JP2024546875A - 二連型ｍｈｃ標的化ｔ細胞エンゲージャー - Google Patents

二連型ｍｈｃ標的化ｔ細胞エンゲージャー Download PDF

Info

Publication number
JP2024546875A
JP2024546875A JP2024535534A JP2024535534A JP2024546875A JP 2024546875 A JP2024546875 A JP 2024546875A JP 2024535534 A JP2024535534 A JP 2024535534A JP 2024535534 A JP2024535534 A JP 2024535534A JP 2024546875 A JP2024546875 A JP 2024546875A
Authority
JP
Japan
Prior art keywords
pmhc
binding
antigen
domain
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024535534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546875A5 (https=
Inventor
ボッラス，レオナルド
ユングミヒェル，シュテファニー
メルテン，ハンネス
ローベルト リヒレ，フィリップ
ベルト シャイフェレ，ファビアン
マリア ソビエライ，アンナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cdr-Life AG
Original Assignee
Cdr-Life AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cdr-Life AG filed Critical Cdr-Life AG
Publication of JP2024546875A publication Critical patent/JP2024546875A/ja
Publication of JP2024546875A5 publication Critical patent/JP2024546875A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024535534A 2021-12-14 2022-12-13 二連型ｍｈｃ標的化ｔ細胞エンゲージャー Pending JP2024546875A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163289380P 2021-12-14 2021-12-14
US63/289,380 2021-12-14
US202263317256P 2022-03-07 2022-03-07
US63/317,256 2022-03-07
US202263328417P 2022-04-07 2022-04-07
US63/328,417 2022-04-07
PCT/EP2022/085689 WO2023110918A1 (en) 2021-12-14 2022-12-13 Dual mhc-targeting t cell engager

Publications (2)

Publication Number Publication Date
JP2024546875A true JP2024546875A (ja) 2024-12-26
JP2024546875A5 JP2024546875A5 (https=) 2025-12-23

Family

ID=84887466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024535534A Pending JP2024546875A (ja) 2021-12-14 2022-12-13 二連型ｍｈｃ標的化ｔ細胞エンゲージャー

Country Status (8)

Country Link
US (1) US20250002586A1 (https=)
EP (1) EP4448570A1 (https=)
JP (1) JP2024546875A (https=)
KR (1) KR20240116828A (https=)
AU (1) AU2022413444A1 (https=)
CA (1) CA3240046A1 (https=)
MX (1) MX2024007473A (https=)
WO (1) WO2023110918A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025210181A1 (en) * 2024-04-04 2025-10-09 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
WO2004016740A2 (en) 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
JP3803790B2 (ja) 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
JP4902674B2 (ja) 2006-03-09 2012-03-21 エフ．ホフマン−ラ ロシュ アーゲー 抗薬物抗体アッセイ法
CA2673470A1 (en) 2006-12-21 2008-07-03 Macrogenics, Inc. Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
RU2009137582A (ru) 2007-03-12 2011-04-20 Эсбатек Аг (Ch) Инженерия и оптимизация одноцепочечных антител на основе последовательности
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
KR20170036814A (ko) 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
BRPI0813645A2 (pt) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
EP2164961B1 (en) 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
CA2728829C (en) 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
KR102211837B1 (ko) 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
JP6594855B2 (ja) 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
IL263466B2 (en) 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
WO2015123315A1 (en) 2014-02-11 2015-08-20 Genzyme Corporation Assays for detecting the presence or amount of an anti-drug antibody
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
US12480957B2 (en) 2017-03-31 2025-11-25 Ablynx N.V. Method of screening for anti-drug antibodies against immunoglobulin single variable domain-based drugs
LT3428194T (lt) * 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
WO2019195535A1 (en) 2018-04-05 2019-10-10 Novartis Ag Trispecific binding molecules against cancers and uses thereof
KR20220015382A (ko) * 2019-05-29 2022-02-08 큐 바이오파마, 인크. 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
EP4025908A4 (en) 2019-09-05 2023-07-19 Adverum Biotechnologies, Inc. ANTI-DRUG ANTIBODY TEST
NL2024375B1 (en) * 2019-12-04 2021-08-31 Apo T B V Methods and means for attracting immune effector cells to tumor cells.
IL293698A (en) * 2019-12-11 2022-08-01 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins, their production and use
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same

Also Published As

Publication number Publication date
CA3240046A1 (en) 2023-06-22
MX2024007473A (es) 2024-09-10
AU2022413444A1 (en) 2024-06-27
EP4448570A1 (en) 2024-10-23
US20250002586A1 (en) 2025-01-02
KR20240116828A (ko) 2024-07-30
WO2023110918A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
AU2018218753A1 (en) Anti-GPRC5D antibody and molecule containing same
US11912771B2 (en) MAGE-A4 peptide-MHC antigen binding proteins
CN112119099A (zh) 三特异性抗原结合蛋白
US12509520B2 (en) Anti-CD3 and anti-CD123 bispecific antibody and use thereof
US12435444B2 (en) Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
US20250144141A1 (en) Mage-a4 peptide dual t cell engagers
TW202246340A (zh) 抗ctla-4抗體及其應用
US20250002586A1 (en) Dual mhc-targeting t cell engager
KR20250042908A (ko) 항-메소텔린 항체 및 이의 용도
US20250333514A1 (en) Antigen binding proteins targeting an hla-restricted prame peptide
CN118679184A (zh) 双重mhc靶向t细胞接合物
CN117751146A (zh) Mage-a4肽-mhc抗原结合蛋白
WO2025210181A1 (en) Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
TW202542204A (zh) 融合蛋白及其用途
CN120659811A (zh) 双特异性抗原结合分子及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241220

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251212